A newly formed data-sharing initiative, Oncology Precision Network (OPeN), is promising a boost to precision medicine via data access to several health systems and cancer patients in the nation.
A newly formed data-sharing initiative, Oncology Precision Network (OPeN)—the product of a collaboration between Intermountain Healthcare, Stanford Cancer Institute, Providence Health and Services, and Syapse—is promising a boost to precision medicine via data access to several health systems and cancer patients in the nation. This announcement was made by the White House press office earlier today, ahead of the Cancer Moonshot Summit organized at Howard University in Washington, DC. Two hundred and seventy events have been planned in parallel to the summit across the United States.
The OPeN network includes 79 hospitals and 800 clinics in 11 states, and is expected to impact 50,000 new cancer cases annually. Additionally, 5 new healthcare systems are projected to onboard over the next 12 months, with a focus on community healthcare systems outside of the existing 11 states. Physicians who are a part of the OPeN network will have access to decision support tools that will be based on data and knowledge sharing so providers across the nation can learn and implement better care practices.
Additionally, OPeN will improve clinical trial participation by providing patients access to new trials in their community. The network will match patients from at least 20 community sites to relevant clinical trials within 15 months.
“The Moonshot cannot be achieved by one person, one organization, one discipline, or even one collective approach,” said Vice President Biden, who heads the Cancer Moonshot effort. “Solving the complexities of cancer will require the formation of new alliances to defy the bounds of innovation and accelerate the prevention, diagnosis, treatment, and—ultimately—a cure. It’s going to require millions of Americans speaking up and contributing what they’re able. That’s what the Cancer Moonshot Summit is all about.”
Several other collaborations and actions have been announced that align with the goals of Cancer Moonshot. These include:
Other initiatives that have been announced can be accessed here.
Real-World Study Reveals Key Insights into DLBCL Treatment Patterns, Outcomes
April 18th 2024A recent study offers valuable insights into the characteristics, treatment patterns, and outcomes of diffuse large B-cell lymphoma (DLBCL) in patients across different lines of therapy, providing a look into the landscape of DLBCL management.
Read More
Pegcetacoplan for PNH More Cost-Effective Than Anti-C5 Monoclonal Antibodies
April 18th 2024A cost-utility analysis conducted from the perspective of the Italian health system found that pegcetacoplan was more effective and less costly than 2 complement 5 (C5) inhibitors for the treatment of paroxysmal nocturnal hemoglobinuria (PNH).
Read More
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
December 19th 2023Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Listen
Many Patients With Psoriasis in Clinical Trials Experience Nocebo Effects, Study Finds
April 18th 2024Half of patients exposed to placebo in clinical trials experienced adverse events (AEs), which may be partially explainable by nocebo effects, according to a recent review and meta-analysis.
Read More
Low-Volume Hospitals Had Higher Reoperation Rate, Postoperative Complications in CRC
April 18th 2024Patients opting for elective colorectal surgery to address colorectal cancer (CRC) could have different rates of reoperation and postoperative complications based on the size of the hospital.
Read More